Back to Search Start Over

June 2014 Phoenix pulmonary journal club: new therapies for IPF and EBUS for sardoidosis

Authors :
Mathew M
Source :
Southwest Journal of Pulmonary and Critical Care, Vol 8, Iss 6, Pp 340-342 (2014)
Publication Year :
2014
Publisher :
Arizona Thoracic Society, 2014.

Abstract

No abstract available. Article truncated at 150 words. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82. Nintedanib is a tyrosine kinase inhibitor that has been shown to decrease the decline of FVC in phase 2 trials of idiopathic pulmonary fibrosis (IPF). This study was a phase 3 trial in which 2 replicate trials comparing nintedanib 150 mg twice daily to placebo. The trials were randomized double blind placebo controlled performed over 205 sites in 24 countries. Inclusion criteria were an age > 40, FVC > 50% and DLCO 30-79%. Patients were excluded if on prednisone > 15 mg/day or any other ...

Details

Language :
English
ISSN :
21606773
Volume :
8
Issue :
6
Database :
Directory of Open Access Journals
Journal :
Southwest Journal of Pulmonary and Critical Care
Publication Type :
Academic Journal
Accession number :
edsdoj.1d14cf8a45924e588a8c79bbf7614036
Document Type :
article
Full Text :
https://doi.org/10.13175/swjpcc078-14